Cargando…

ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.

The combined effect of the chemotherapeutic agent ICRF-159 and irradiation were evaluated using the Lewis lung tumour (LL). At a daily dose of 25 mg/kg, ICOF given alone prevented the progressive growth of LL. Daily pretreatment also potentiated the effects of radiation (600 rad) on tumour growth, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovacs, C. J., Evans, M. J., Schenken, L. L., Burholt, D. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1979
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009898/ https://www.ncbi.nlm.nih.gov/pubmed/486307

Ejemplares similares

ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
por: Kovacs, C. J., et al.
Publicado: (1979)

in vitro effects of ICRF 159.
por: Hellmann, K., et al.
Publicado: (1973)

Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
por: Taylor, I. W., et al.
Publicado: (1977)

The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
por: Albanese, R., et al.
Publicado: (1985)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159.
por: Hellmann, K., et al.
Publicado: (1974)

Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
por: Zwilling, B. S., et al.
Publicado: (1981)

Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro.
por: Taylor, I. W., et al.
Publicado: (1977)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.
por: Edgar, D. H., et al.
Publicado: (1981)

Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II).
por: Kovacs, C. J., et al.
Publicado: (1982)

Responses of an experimental solid tumour to irradiation: A comparison of modes of fractionation.
por: Schenken, L. L., et al.
Publicado: (1975)

The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
por: de Ridder, Sander, et al.
Publicado: (2020)

The effects of ICRF-154 in combination with other anticancer agents in vitro.
por: Kano, Y., et al.
Publicado: (1992)

Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
por: Perkins, W. E., et al.
Publicado: (1982)

Abstract 159: Glomus tumour presenting with oncogenic osteomalacia
por: Mathew, Anu
Publicado: (2022)

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
por: Meikle, I., et al.
Publicado: (1996)

The Dose-response Relationship of the Ehrlich Ascites Tumour
por: Warner, Peter, et al.
Publicado: (1959)

Solid tumour models for the assessment of different treatment modalities: IV. the combined effects of radiation and 5-fluorouracil.
por: Looney, W. B., et al.
Publicado: (1976)

Molecular Characterization of Human Papillomavirus Type 159 (HPV159)
por: Marković, Iva, et al.
Publicado: (2021)

Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
por: Shah, S, et al.
Publicado: (2002)

Moments, monodromy, and perversity (AM-159): a Diophantine perspective (AM-159)
por: Katz, Nicholas M
Publicado: (2005)

A Unified Dose Response Relationship to Predict High Dose Fractionation Response in the Lung Cancer Stereotactic Body Radiation Therapy
por: Kehwar, Than S., et al.
Publicado: (2017)

Radiation dose for thymic tumours
por: Lalani, Nafisha, et al.
Publicado: (2020)

Renal and haemopoietic proliferative defects as a delayed consequence of cis-platin, adriamycin and daunomycin treatments.
por: Braunschweiger, P. G., et al.
Publicado: (1982)

The quantitative response of human tumours to radiation and misonidazole.
por: Ash, D. V., et al.
Publicado: (1979)

Discussion on P-159 proposal
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1981)

159th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2002)

ETC-159, an Upstream Wnt inhibitor, Induces Tumour Necrosis via Modulation of Angiogenesis in Osteosarcoma
por: Chua, Kenon, et al.
Publicado: (2023)

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness
por: Ahsan, Tamim, et al.
Publicado: (2020)

Dexamethasone and radiation response in the Lewis lung tumour model.
por: Agboola, O. O., et al.
Publicado: (1983)

Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours
por: Farrer, Nicola J., et al.
Publicado: (2022)

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
Publicado: (1994)

Status report of the "dibaryon" experiment S159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1979)

Job burnout in 159 anesthesiology trainees
por: Abut, Yesim Cokay, et al.
Publicado: (2012)

Dose-response relationship in multistage carcinogenesis: promoters.
por: Kitchin, K T, et al.
Publicado: (1994)

Radiation-induced disease: Problems of response in relation to dose, dose-rate and radiation quality
por: Burch, P J
Publicado: (1971)

Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk
por: Moghadampour, Mehdi, et al.
Publicado: (2016)

IAU Symposium 159 : Active Galactic Nuclei across the Electromagnetic Spectrum
por: Blecha, A, et al.
Publicado: (1993)

Alteration of tumour response to radiation by interleukin-2 gene transfer
por: Lee, J, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_d2jessua5q29j6bp5lp84ea2du